A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The aims of this study are:
- To evaluate the benefits of the addition of bortezomib to standard rituximab with
cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in Diffuse
Large B-cell Lymphoma (DLBCL).
- To determine whether molecular phenotype effects the benefits derived from the addition
of bortezomib.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust